title: [Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
authors: N G
authors: NG
authors: Gogolashvili
mesh_terms: D000069059:Atorvastatin; D001682:Biological Availability; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000493:pharmacokinetics; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics; D011758:Pyrroles / Q000008:administration & dosage / Q000493:pharmacokinetics; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D055502:Secondary Prevention / Q000379:methods / Q000592:standards; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics; D013810:Therapeutic Equivalency
chemical_list: D005464:Fluorobenzenes; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin